Table 4.
Comparison of Proportion of Participants With Pathologic Parameters in Weight, Fasting Glucose, and Lipid Levels at Baseline and at 1-Year Follow-up in Each Treatment Group
| Metabolic conditions | 1-Year follow-up | Baseline | |||
|---|---|---|---|---|---|
| % (n) | % (n) | % Difference | n | P a | |
| BMI ≥30 kg/m2 | |||||
| Aripiprazole group | 10.5 (9) | 3.5 (3) | 10.0 | 86 | .041 |
| Risperidone group | 19.8 (18) | 7.7 (7) | 12.1 | 91 | .003 |
| Total | 15.3 (27) | 5.6 (10) | 9.6 | 177 | <.001 |
| Metabolic syndrome | |||||
| Aripiprazole group | 10.3(9) | 1.1(1) | 9.2 | 87 | .027 |
| Risperidone group | 8.6(8) | 4.3(4) | 4.3 | 93 | .289 |
| Total | 9.4(17) | 2.8(5) | 6.7 | 180 | .010 |
| Glucose>110 mg/dL | |||||
| Aripiprazole group | 2.4 (2) | 0 | 2.3 | 85 | .480 |
| Risperidone group | 3.3 (3) | 0 | 3.3 | 90 | .248 |
| Total | 2.9 (5) | 0 | 2.9 | 175 | .074 |
| Insulin, µU/mL; men>15.7, women>17.3 | |||||
| Aripiprazole group | 9.4(8) | 7.1(6) | 2.4 | 85 | .773 |
| Risperidone group | 14.6(13) | 7.9(7) | 6.7 | 89 | .211 |
| Total | 12.1(21) | 7.5(13) | 4.6 | 174 | .186 |
| HOMA; men>3.5, women>3.9 | |||||
| Aripiprazole group | 7.1(6) | 5.9(5) | 1.2 | 85 | 1.000 |
| Risperidone group | 12.5(11) | 8.0(7) | 4.5 | 88 | .423 |
| Total | 9.8(17) | 6.9(12) | 2.9 | 173 | .424 |
| Triglyceride/HDL index>3.5 | |||||
| Aripiprazole group | 22.5 (16) | 7.0 (5) | 15.5 | 7 | .010 |
| Risperidone group | 19.4 (14) | 5.6 (4) | 13.9 | 72 | .009 |
| Total | 21.0 (30) | 6.3 (9) | 14.7 | 143 | <.001 |
| Cholesterol >200mg/dL | |||||
| Aripiprazole group | 36.5 (31) | 11.8 (10) | 24.7 | 85 | <.001 |
| Risperidone group | 34.1 (30) | 17.0 (15) | 17.1 | 88 | .002 |
| Total | 35.3 (61) | 14.5 (25) | 20.8 | 173 | <.001 |
| LDL cholesterol >130mg/dL | |||||
| Aripiprazole group | 34.3 (24) | 14.3 (10) | 20.0 | 70 | .002 |
| Risperidone group | 28.6 (20) | 12.9 (9) | 15.7 | 70 | .010 |
| Total | 31.4 (44) | 13.6 (19) | 17.9 | 140 | <.001 |
| HDL cholesterol <40mg/dL | |||||
| Aripiprazole group | 19.7 (14) | 18.3 (13) | 1.4 | 71 | 1.000 |
| Risperidone group | 12.5 (9) | 12.5 (9) | 0 | 72 | 1.000 |
| Total | 16.1 (23) | 15.4 (22) | 0.7 | 143 | 1.000 |
| Triglycerides >150mg/dL | |||||
| Aripiprazole group | 23.3 (17) | 1.4 (1) | 21.9 | 73 | <.001 |
| Risperidone group | 13.3 (10) | 5.3 (4) | 8.0 | 75 | .149 |
| Total | 18.2 (27) | 3.4 (5) | 14.9 | 148 | <.001 |
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; HOMA, homeostasis model assessment; LDL, low-density lipoprotein.
a McNemar test for repeated measures.